NCT06335693 Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
| NCT ID | NCT06335693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changhai Hospital |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2024-03-28 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 9 participants in total. It began in 2024-03-28 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the safety and feasibility of adjuvant hypofractionated radiotherapy following radical prostatectomy for prostate cancer.
Eligibility Criteria
Inclusion Criteria: 1. ECOG performance status 0-2. 2. Pathologically confirmed prostate cancer and completion of radical prostatectomy. 3. Postoperative pathological staging pT 3a, pT 3b, pT 4, surgical margins (+) or N1; or serum PSA ≥0.1ng/ml at 6 weeks postoperatively; or serum PSA \<0.1ng/ml at 6 weeks postoperatively, with two consecutive persistently elevated PSA (≥0.1ng/ml) without signs of metastasis on clinical imaging (whole-body bone scan (ECT), magnetic resonance imaging (MRI), 68Ga PSMA PET/CT, etc.) . 4. Expected survival time \>5 years. 5. Voluntarily accepted this experimental study protocol after being informed of the available treatment options. Exclusion Criteria: 1. Patients with poor recovery of continence after radical prostatectomy. 2. Patients with a history of pelvic and abdominal radiotherapy. 3. Patients who participated in other clinical trials that were repugnant to the intervention of this trial within 4 weeks prior to the start of this trial. 4. Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis. 5. Patients who are deemed unfit to participate in this clinical trial in the judgement of the investigator, for instance, patients with serious systemic diseases that, in the judgement of the investigator, may interfere with the treatment and evaluation of this trial and its compliance, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immunological, urological and other systemic diseases. 6. Patients with radiotherapy-related contraindications. 7. Patients who cannot provide written informed consent and have poor adherence to treatment.
Contact & Investigator
Huojun Zhang, PhD
STUDY DIRECTOR
Changhai Hospital
Frequently Asked Questions
Who can join the NCT06335693 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06335693 currently recruiting?
Yes, NCT06335693 is actively recruiting participants. Contact the research team at huojunzh@163.com for enrollment information.
Where is the NCT06335693 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06335693 clinical trial?
NCT06335693 is sponsored by Changhai Hospital. The principal investigator is Huojun Zhang, PhD at Changhai Hospital. The trial plans to enroll 9 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.